CorLab Competitors

Clear and confident health care decisions begin with questions. At Labcorp, we’re constantly in pursuit of answers. As a global leader of innovative and comprehensive laboratory services, we help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Our more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about Labcorp (NYSE: LH) at www.labcorp.com.

StatLab Medical Products has been dedicated to helping anatomic pathology laboratories provide the best possible patient care since 1976. We offer an extensive portfolio of self-manufactured consumables and labeling and tracking equipment from nine manufacturing sites in the United States, United Kingdom, Germany, Spain, and Italy. Our global operational footprint powered by over 800 mission-driven colleagues delivers a dependable and resilient supply chain of high-quality products and solutions, and a customer-centric approach inspires us to deliver reliability, innovation, and quality in every interaction.

In 2022, TECHLAB was acquired by SSI Diagnostica Group. Today, TECHLAB functions as a brand under SSI Diagnostica Group. About SSI Diagnostica Group: SSI Diagnostica Group is a global in vitro diagnostics (IVD) company, specializing in infectious disease diagnostics. We employ staff and operate offices in Denmark, the United States, and China, with a total of eleven sites across three different continents. Each year, we deliver diagnostic solutions in more than 130 countries and manufacture more than 60 million diagnostic tests – helping people receive the right diagnosis and, ultimately, the right treatment as quickly as possible. Operating as one company today, SSI Diagnostica Group is historically the result of a series of acquisitions: SSI Diagnostica (2016), CTK Biotech (2020), Beijing Genesee Biotech (2020), Techlab (2022), Gulf Coast Scientific (2025), and InDevR (2026). Each brand has brought unique expertise and experience to the group, and as a combined company we offer more than 200 years of combined scientific expertise. SSID Group’s mission is to empower healthcare professionals to prevent, monitor, and diagnose infectious diseases – enabling better treatment outcomes for patients worldwide. SSI Diagnostica group has four disease focus areas: Gastric, Respiratory, Bloodborne, and general microbiology.